AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35343716 — intervention group
Group type: EXPERIMENTAL
Intervention: Guilt condition (induced with guilt using a revised mishap paradigm)
Number of subjects: 192
Study 35343716 — intervention group
Group type: COMPARATOR
Intervention: Sadness condition (induced with sadness by watching a video)
Number of subjects: 192
Study 35343716 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition (no additional emotion-inducing task)
Number of subjects: 192
Study 34479543 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (100 mg daily)
Number of subjects: 233
Study 34479543 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (starting dose 0.5 mg daily)
Number of subjects: 233
Study 32258159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of muscle energy technique (MET) and ischemic compression technique (ICT) along with conventional intervention
Number of subjects: 60
Study 32258159 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle energy technique (MET) and conventional intervention (without ICT)
Number of subjects: 60
Study 32258159 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 60
Study 35469230 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic aspiration (n = 26)
Number of subjects: 50
Study 35469230 — intervention group
Group type: COMPARATOR
Intervention: Decompressive craniectomy (n = 24)
Number of subjects: 50
Study 33908058 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis ssp. lactis 420 (B420)
Number of subjects: 50
Study 33908058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 32350180 — intervention group
Group type: EXPERIMENTAL
Intervention: Kombu (Laminaria japonica) intake for 4 weeks
Number of subjects: 0
Study 32350180 — intervention group
Group type: EXPERIMENTAL
Intervention: Kombu (Laminaria japonica) intake
Number of subjects: 0
Study 34932832 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (8-week duration)
Number of subjects: 57
Study 34932832 — intervention group
Group type: COMPARATOR
Intervention: Inactive control
Number of subjects: 57
Study 33606173 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Prepared
Number of subjects: 397
Study 33606173 — intervention group
Group type: COMPARATOR
Intervention: TEEN (control)
Number of subjects: 397
Study 32327087 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early invasive strategy (EG) with coronary angiography (CA) within 2 hours
Number of subjects: 741
Study 32327087 — intervention group
Group type: COMPARATOR
Intervention: Delayed invasive strategy (DG) with coronary angiography (CA) performed 12 to 72 hours after randomization
Number of subjects: 741
Study 32327087 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early invasive strategy (EG)
Number of subjects: 741
Study 32327087 — intervention group
Group type: COMPARATOR
Intervention: Delayed invasive strategy (DG)
Number of subjects: 741
Study 36495690 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session mini-course derived from a guided chat-based intervention
Number of subjects: 525
Study 33011684 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression sutures combined with intracameral air injection (CSAI)
Number of subjects: 20
Study 33011684 — intervention group
Group type: COMPARATOR
Intervention: Thermokeratoplasty (TKP)
Number of subjects: 20
Study 33677745 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D virtual reality (VR) headset
Number of subjects: 51
Study 33677745 — intervention group
Group type: COMPARATOR
Intervention: Desktop (DT) computer interface
Number of subjects: 51
Study 32026844 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Rehabilitation
Number of subjects: 51
Study 32026844 — intervention group
Group type: COMPARATOR
Intervention: Conventional Rehabilitation
Number of subjects: 51
Study 35044989 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led online community
Number of subjects: 900
Study 35044989 — intervention group
Group type: COMPARATOR
Intervention: Control group (no peer leaders)
Number of subjects: 900
Study 32895332 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use duodenoscope
Number of subjects: 98
Study 32895332 — intervention group
Group type: COMPARATOR
Intervention: Reusable duodenoscope
Number of subjects: 98
Study 32513581 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg soy isoflavone daily for 8 weeks
Number of subjects: 40
Study 32513581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 36476258 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid Vi-polysaccharide conjugate vaccine (Typbar-TCV®) and measles vaccine (MV) concomitantly at 9 months (Group 1)
Number of subjects: 493
Study 36476258 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid Vi-polysaccharide conjugate vaccine (Typbar-TCV®) and measles vaccine (MV) on Day 0 and Day 28 (Group 2)
Number of subjects: 493
Study 36476258 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid Vi-polysaccharide conjugate vaccine (Typbar-TCV®) at 8 months and MV 28 days later (Group 3)
Number of subjects: 493
Study 36476258 — intervention group
Group type: COMPARATOR
Intervention: Measles vaccine only at 9 months (Group 4)
Number of subjects: 493
Study 33511671 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental simulation intervention
Number of subjects: 0
Study 33511671 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32559353 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA radioligand therapy (RLT) with 177Lu (Lu-PSMA)
Number of subjects: 0
Study 36326742 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified uvulopalatopharyngoplasty (mUPPP)
Number of subjects: 93
Study 36326742 — intervention group
Group type: COMPARATOR
Intervention: Tonsillectomy (TE)
Number of subjects: 93
Study 33402209 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin supplementation
Number of subjects: 850
Study 33402209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study 36057025 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Group Intervention (BGI) using the FRAMES model
Number of subjects: 112
Study 36057025 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) standard service
Number of subjects: 112
Study 36057025 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Group Intervention (BGI)
Number of subjects: 112
Study 33745724 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged infertility (≥60 months)
Number of subjects: 104
Study 33745724 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended TTP (≥36 months)
Number of subjects: 104
Study 33745724 — intervention group
Group type: COMPARATOR
Intervention: Fertile controls (0 months)
Number of subjects: 104
Study 35016670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Number of subjects: 46
Study 35016670 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrater reliability assessment
Number of subjects: 46
Study 35382793 — intervention group
Group type: EXPERIMENTAL
Intervention: PLAYshop intervention (75-min in-person workshop, educational materials, equipment pack, two post-workshop booster emails)
Number of subjects: 143
Study 35382793 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention details provided)
Number of subjects: 143
Study 32830894 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg IV
Number of subjects: 45
Study 32830894 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 600 mg IV
Number of subjects: 45
Study 32830894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 35642699 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) training
Number of subjects: 16
Study 35642699 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 16
Study 34625562 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (cALND)
Number of subjects: 1855
Study 34625562 — intervention group
Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy (SLNB) alone
Number of subjects: 1855
Study 34625562 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC) after ALND
Number of subjects: 1855
Study 34625562 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (AC) before ALND
Number of subjects: 1855
Study 36423444 — intervention group
Group type: COMPARATOR
Intervention: No preparation
Number of subjects: 161
Study 36423444 — intervention group
Group type: COMPARATOR
Intervention: Oral antibiotic bowel preparation (OABP)
Number of subjects: 161
Study 36423444 — intervention group
Group type: COMPARATOR
Intervention: OABP plus mechanical bowel preparation (MBP)
Number of subjects: 161
Study 36423444 — intervention group
Group type: EXPERIMENTAL
Intervention: OABP
Number of subjects: 161
Study 36423444 — intervention group
Group type: EXPERIMENTAL
Intervention: OABP+MBP
Number of subjects: 161
Study 34338231 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline added to standard antituberculous therapy (ATT) for 2 weeks
Number of subjects: 0
Study 34338231 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to standard antituberculous therapy (ATT)
Number of subjects: 0
Study 32827483 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronomic chemotherapy (15 mg/m2 methotrexate once per week plus 200 mg celecoxib twice per day until disease progression or intolerable side effects)
Number of subjects: 422
Study 32827483 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cisplatin (75 mg/m2 once every 3 weeks for six cycles)
Number of subjects: 422
Study 32827483 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronomic chemotherapy
Number of subjects: 422
Study 32827483 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cisplatin
Number of subjects: 422
Study 33684325 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (20, 75-min, in-person, group, gentle yoga classes held twice weekly)
Number of subjects: 0
Study 33684325 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 0
Study 33684325 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 35368921 — intervention group
Group type: EXPERIMENTAL
Intervention: syndrome-position point selection method (acupuncture at corresponding acupoints)
Number of subjects: 100
Study 35368921 — intervention group
Group type: EXPERIMENTAL
Intervention: syndrome-position point selection method
Number of subjects: 100
Study 35368921 — intervention group
Group type: COMPARATOR
Intervention: traditional acupuncture method
Number of subjects: 100
Study 34151602 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive virtual reality treatment over ten sessions
Number of subjects: 6
Study 34151602 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive virtual reality treatment
Number of subjects: 6
Study 34151602 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 6
Study 32162103 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (low dose)
Number of subjects: 71
Study 32162103 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 71
Study 35477628 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine ODF 180 mcg
Number of subjects: 760
Study 35477628 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine ODF 120 mcg
Number of subjects: 760
Study 35477628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760
Study 35477628 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine ODF (both doses)
Number of subjects: 760
Study 32937627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical administration of melatonin (25 mg)
Number of subjects: 10
Study 32937627 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of melatonin (25 mg)
Number of subjects: 10
Study 32937627 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal administration of melatonin (25 mg)
Number of subjects: 10
Study 32937627 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of melatonin (25 mg)
Number of subjects: 10
Study 32937627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of melatonin (25 mg)
Number of subjects: 10
Study 35414560 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 30
Study 35414560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 34288578 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil (200 mg) under fasting conditions
Number of subjects: 100
Study 34288578 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil (200 mg) under fed conditions
Number of subjects: 100
Study 34288578 — intervention group
Group type: COMPARATOR
Intervention: Avanafil (200 mg)
Number of subjects: 100
Study 35437959 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated Foley catheter (case group)
Number of subjects: 85
Study 35437959 — intervention group
Group type: COMPARATOR
Intervention: Conventional non-coated Foley catheter (control group)
Number of subjects: 85
Study 33597336 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic administration of vitamin C (600 mg)
Number of subjects: 30
Study 33597336 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of local and systemic administration of vitamin C (600 mg)
Number of subjects: 30
Study 33597336 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin C administration)
Number of subjects: 30
Study 35417075 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education for parents
Number of subjects: 2594
Study 35417075 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching parents/teachers to use negative consequences
Number of subjects: 2594
Study 35417075 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual training
Number of subjects: 2594
Study 32299106 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotomy at 6 to <8 hours after oxytocin
Number of subjects: 2854
Study 32299106 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotomy at time intervals ≥4 hours after oxytocin
Number of subjects: 2854
Study 32299106 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotomy at time intervals ≥2 hours and <8 hours after oxytocin
Number of subjects: 2854
Study 32299106 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotomy
Number of subjects: 2854
Study 32299106 — intervention group
Group type: COMPARATOR
Intervention: No amniotomy
Number of subjects: 2854
Study 33207670 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) program as a complementary tool to conventional cardiac rehabilitation (CR) program
Number of subjects: 0
Study 33207670 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group (Control Group)
Number of subjects: 0
Study 34560141 — intervention group
Group type: EXPERIMENTAL
Intervention: Opponent tended to be competitive (cooperative 20% of the time)
Number of subjects: 0
Study 34560141 — intervention group
Group type: COMPARATOR
Intervention: Opponent tended to be cooperative (cooperative 80% of the time)
Number of subjects: 0
Study 32595244 — intervention group
Group type: EXPERIMENTAL
Intervention: WS 1442 2x450 mg/day (WS-standard)
Number of subjects: 60
Study 32595244 — intervention group
Group type: EXPERIMENTAL
Intervention: WS 1442 2x900 mg/day (WS-double)
Number of subjects: 60
Study 32595244 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 2x30 minutes/week (NW-low)
Number of subjects: 60
Study 32595244 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 4x45 minutes/week (NW-high)
Number of subjects: 60
Study 32190684 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular vagus nerve stimulation and 20 sessions of a home‐based exercise program
Number of subjects: 60
Study 32190684 — intervention group
Group type: COMPARATOR
Intervention: Home‐based exercise program
Number of subjects: 60
Study 33317422 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 39
Study 33317422 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 39
Study 32119742 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive Zinc Supplementation (PZ; 7 mg Zn/d)
Number of subjects: 512
Study 32119742 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo powder)
Number of subjects: 512
Study 32490642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment
Number of subjects: 1247
Study 32490642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment with aspirin
Number of subjects: 1247
Study 32490642 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 1247
Study 32490642 — intervention group
Group type: EXPERIMENTAL
Intervention: Blacks
Number of subjects: 1247
Study 32490642 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD)
Number of subjects: 1247
Study 32490642 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1247
Study 32201572 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesiology control tower (ACT)
Number of subjects: 58
Study 32201572 — intervention group
Group type: COMPARATOR
Intervention: No intervention (standard of anesthesia care)
Number of subjects: 58
Study 35719232 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue intervention with dominant plantar flexors (two 100-s MVICs with 60-s recovery)
Number of subjects: 16
Study 35719232 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (rested for 260-s)
Number of subjects: 16
Study 35719232 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue intervention
Number of subjects: 16
Study 35719232 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated MVICs after fatigue intervention
Number of subjects: 16
Study 33784735 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept injections (2.0 mg)
Number of subjects: 328
Study 33784735 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 328
Study 32242987 — intervention group
Group type: EXPERIMENTAL
Intervention: P. palmata (2 g/day)
Number of subjects: 104
Study 32242987 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 104
Study 35313201 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (20 Hz) at 85% of the MT, 25 trains of 5 s duration, total of 2500 pulses/session, applied over the left DLPFC for five consecutive days per week, for two weeks
Number of subjects: 28
Study 33534082 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram prediction calculator for postoperative mortality
Number of subjects: 0
Study 34332629 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exclusive human-milk diet devoid of bovine-milk-based food components
Number of subjects: 200
Study 34332629 — intervention group
Group type: COMPARATOR
Intervention: Control group of term-born infants
Number of subjects: 200
Study 34332629 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 200
Study 32197493 — intervention group
Group type: EXPERIMENTAL
Intervention: iTIS (instrumented Trunk Impairment Scale) using the Valedo system
Number of subjects: 40
Study 32197493 — intervention group
Group type: COMPARATOR
Intervention: TIS (Trunk Impairment Scale)
Number of subjects: 40
Study 33909135 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy (chemoradiotherapy)
Number of subjects: 4279
Study 33909135 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonectomy
Number of subjects: 4279
Study 33909135 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobectomy
Number of subjects: 4279
Study 33909135 — intervention group
Group type: COMPARATOR
Intervention: Upfront surgery (Lobectomy)
Number of subjects: 4279
Study 33909135 — intervention group
Group type: COMPARATOR
Intervention: Upfront surgery (Pneumonectomy)
Number of subjects: 4279
Study 33909135 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobectomy vs Pneumonectomy
Number of subjects: 4279
Study 36457355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical Lactobacillus rhamnosus GG
Number of subjects: 120
Study 36457355 — intervention group
Group type: COMPARATOR
Intervention: Saline bladder wash
Number of subjects: 120
Study 32205243 — intervention group
Group type: EXPERIMENTAL
Intervention: Training series
Number of subjects: 600
Study 32205243 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation series
Number of subjects: 600
Study 35857290 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical synthetic hypericin ointment, 0.25%, activated with visible light, applied to 3 index lesions twice weekly for 6 weeks (Cycle 1)
Number of subjects: 169
Study 35857290 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical synthetic hypericin ointment, 0.25%, activated with visible light, applied to index lesions for 6 weeks (Cycle 2)
Number of subjects: 169
Study 35857290 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical synthetic hypericin ointment, 0.25%, activated with visible light, applied to index and additional lesions for 6 weeks (Cycle 3)
Number of subjects: 169
Study 35857290 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied to 3 index lesions twice weekly for 6 weeks (Cycle 1)
Number of subjects: 169
Study 35857290 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical synthetic hypericin ointment, 0.25%, activated with visible light (all cycles)
Number of subjects: 169
Study 32737388 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight (LBW) in men
Number of subjects: 8278
Study 32737388 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight (LBW) in women
Number of subjects: 8278
Study 34108180 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus Trametinib
Number of subjects: 146
Study 34108180 — intervention group
Group type: EXPERIMENTAL
Intervention: High B-cell signatures
Number of subjects: 146
Study 34010952 — intervention group
Group type: EXPERIMENTAL
Intervention: Coherently disarrayed sequences
Number of subjects: 243
Study 34010952 — intervention group
Group type: COMPARATOR
Intervention: Incoherently disarrayed sequences
Number of subjects: 243
Study 34010952 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut feeling response
Number of subjects: 243
Study 34010952 — intervention group
Group type: EXPERIMENTAL
Intervention: Sure response
Number of subjects: 243